Skip to main content

THE FIRST TREATMENT FOR EoE
PATIENTS AS YOUNG AS 1 YEAR OLD

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).1
TRANSFORM THE WAY
YOU MANAGE EoE

Discover clinical, histologic,
and
endoscopic results1-3

FDA-APPROVED in children as
young as 1 year with EoE (≥15 kg)1

May 22 is the first-ever
World EoE Day!

Patients around the globe
are standing up to EoE

JOIN THE MOVEMENT

US.DUP.25.04.0843

EXPLORE UP TO 52 WEEKS OF DATA FOR BOTH GROUPS1-3

Adult and teen wearing green shirts smiling

Adults/Adolescents
(12+ years)

VIEW THE Efficacy RESULTS EXPLORE THE Safety DATA
two children one boy and one girl both smiling

Children (1-11 years)

VIEW THE Efficacy RESULTS EXPLORE THE Safety DATA
DUPIXENT MyWay® Logo

DUPIXENT MyWay® is a patient support
program
that can help
enable access to
DUPIXENT
and offers financial assistance
for
eligible
patients, one-on-one nursing
support, and more.

LEARN HOW WE CAN HELP

DUPIXENT MyWay
ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Contact a Field
Representative

Connect with a DUPIXENT Field Representative to get answers to your product-related questions.

CONTACT A REP